BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

354 related articles for article (PubMed ID: 29579127)

  • 21. The association between timing of initiation of adjuvant therapy and the survival of early stage ovarian cancer patients - An analysis of NRG Oncology/Gynecologic Oncology Group trials.
    Chan JK; Java JJ; Fuh K; Monk BJ; Kapp DS; Herzog T; Bell J; Young R
    Gynecol Oncol; 2016 Dec; 143(3):490-495. PubMed ID: 27771168
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preoperative serum 8-hydroxydeoxyguanosine is associated with chemoresistance and is a powerful prognostic factor in endometrioid-type epithelial ovarian cancer.
    Pylväs-Eerola M; Karihtala P; Puistola U
    BMC Cancer; 2015 Jul; 15():493. PubMed ID: 26134400
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Does the primary route of spread have a prognostic significance in stage III non-serous epithelial ovarian cancer?
    Sahin H; Meydanli MM; Sari ME; Yalcin I; Çoban G; Ozkan NT; Cuylan ZF; Erdem B; Gungorduk K; Akbayir Ö; Dede M; Salman MC; Güngör T; Ayhan A
    J Ovarian Res; 2018 Mar; 11(1):21. PubMed ID: 29506569
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Feto-maternal outcomes of pregnancy complicated by epithelial ovarian cancer: a systematic review of literature.
    Blake EA; Kodama M; Yunokawa M; Ross MS; Ueda Y; Grubbs BH; Matsuo K
    Eur J Obstet Gynecol Reprod Biol; 2015 Mar; 186():97-105. PubMed ID: 25668134
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HE4 as a predictor of adjuvant chemotherapy resistance and survival in patients with epithelial ovarian cancer.
    Aarenstrup Karlsen M; Høgdall C; Nedergaard L; Philipsen Prahm K; Schou Karlsen NM; Weng Ekmann-Gade A; Henrichsen Schnack T; Svenstrup Poulsen T; Jarle Christensen I; Høgdall E
    APMIS; 2016 Dec; 124(12):1038-1045. PubMed ID: 27859687
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prognostic factors for high-risk early-stage epithelial ovarian cancer: a Gynecologic Oncology Group study.
    Chan JK; Tian C; Monk BJ; Herzog T; Kapp DS; Bell J; Young RC;
    Cancer; 2008 May; 112(10):2202-10. PubMed ID: 18348296
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [Re-evaluation of interval debulking surgery in advanced epithelial ovarian cancer].
    Ma Y; Li Y; Cui H; Liang XD; Tang ZJ; Li XP; Zhao Y; Wei LH
    Zhonghua Fu Chan Ke Za Zhi; 2012 May; 47(5):355-60. PubMed ID: 22883524
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Recurrence season impacts the survival of epithelial ovarian cancer patients.
    Liu XH; Man YN; Wu XZ
    Asian Pac J Cancer Prev; 2014; 15(4):1627-32. PubMed ID: 24641379
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intraperitoneal chemotherapy for recurrent epithelial ovarian cancer is feasible with high completion rates, low complications, and acceptable patient outcomes.
    Skaznik-Wikiel ME; Lesnock JL; McBee WC; Beriwal S; Zorn KK; Richard SD; Krivak TC; Edwards RP
    Int J Gynecol Cancer; 2012 Feb; 22(2):232-7. PubMed ID: 22080886
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Clinical relevance of CD44 surface expression in advanced stage serous epithelial ovarian cancer: a prospective study.
    Elzarkaa AA; Sabaa BE; Abdelkhalik D; Mansour H; Melis M; Shaalan W; Farouk M; Malik E; Soliman AA
    J Cancer Res Clin Oncol; 2016 May; 142(5):949-58. PubMed ID: 26762850
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Poor performance status (PS) is an indication for an aggressive approach to neoadjuvant chemotherapy in patients with advanced epithelial ovarian cancer (EOC).
    Seifert H; Georgiou A; Alexander H; McLachlan J; Bodla S; Kaye S; Barton D; Nobbenhuis M; Gore M; Banerjee S
    Gynecol Oncol; 2015 Nov; 139(2):216-20. PubMed ID: 26318078
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Long-term clinical outcome of patients with recurrent epithelial ovarian carcinoma: is it the same for each histological type?
    Kajiyama H; Shibata K; Mizuno M; Umezu T; Suzuki S; Yamamoto E; Fujiwara S; Kawai M; Nagasaka T; Kikkawa F
    Int J Gynecol Cancer; 2012 Mar; 22(3):394-9. PubMed ID: 22391762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Trends in therapy and survival of advanced stage epithelial ovarian cancer patients in the Netherlands.
    van Altena AM; Karim-Kos HE; de Vries E; Kruitwagen RF; Massuger LF; Kiemeney LA
    Gynecol Oncol; 2012 Jun; 125(3):649-54. PubMed ID: 22370602
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic Significance of Preoperative Prognostic Nutritional Index in Epithelial Ovarian Cancer Patients Treated with Platinum-Based Chemotherapy.
    Miao Y; Li S; Yan Q; Li B; Feng Y
    Oncol Res Treat; 2016; 39(11):712-719. PubMed ID: 27855385
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Nomograms Predicting Platinum Sensitivity, Progression-Free Survival, and Overall Survival Using Pretreatment Complete Blood Cell Counts in Epithelial Ovarian Cancer.
    Paik ES; Sohn I; Baek SY; Shim M; Choi HJ; Kim TJ; Choi CH; Lee JW; Kim BG; Lee YY; Bae DS
    Cancer Res Treat; 2017 Jul; 49(3):635-642. PubMed ID: 27669704
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Placenta Growth Factor Is Associated with Unfavorable Prognosis of Advanced-Stage Serous Ovarian Cancer.
    Meng Q; Duan P; Li L; Miao Y
    Tohoku J Exp Med; 2018 Apr; 244(4):291-296. PubMed ID: 29643276
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The impact of lymph node dissection and adjuvant chemotherapy on survival: A nationwide cohort study of patients with clinical early-stage ovarian cancer.
    Kleppe M; van der Aa MA; Van Gorp T; Slangen BF; Kruitwagen RF
    Eur J Cancer; 2016 Oct; 66():83-90. PubMed ID: 27536891
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prognostic relevance of uncommon ovarian histology in women with stage III/IV epithelial ovarian cancer.
    Mackay HJ; Brady MF; Oza AM; Reuss A; Pujade-Lauraine E; Swart AM; Siddiqui N; Colombo N; Bookman MA; Pfisterer J; du Bois A;
    Int J Gynecol Cancer; 2010 Aug; 20(6):945-52. PubMed ID: 20683400
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clear cell carcinomas of the ovary have poorer outcomes compared with serous carcinomas: Results from a single-center Taiwanese study.
    Ku FC; Wu RC; Yang LY; Tang YH; Chang WY; Yang JE; Wang CC; Jung SM; Lin CT; Chang TC; Chao A; Lai CH
    J Formos Med Assoc; 2018 Feb; 117(2):117-125. PubMed ID: 28389144
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Clinical characteristics of borderline ovarian tumors and stage I epithelial ovarian cancer: an analysis of 143 cases].
    Zhao Y; Wang Y; Shen Dh; Song Rn; Xu Q; Li Y; Cui H; Tang J; Wei Lh
    Beijing Da Xue Xue Bao Yi Xue Ban; 2011 Feb; 43(1):123-8. PubMed ID: 21321635
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 18.